Frontage Laboratories and Spaulding Clinical Research have entered into an agreement to strengthen their expertise in China.
Under the agreement, Frontage will combine its drug formulation and Bioanalytical analysis expertise with Spaulding Clinical’s Cardiac Safety and fully-automated Clinical Pharmacology facility.
Spaulding Clinical will conduct all electrocardiographic studies in its facility and will offer ECG Core Lab services on behalf of Frontage.
Frontage will offer bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding Clinical.
Spaulding CEO and founder Randy Spaulding said together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China.
